A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men.

@article{Olsen2007AMR,
  title={A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men.},
  author={Elise A. Olsen and David Whiting and Wilma Fowler Bergfeld and Jeffrey F. Miller and Maria Hordinsky and Rita A Wanser and Paul L. Zhang and Bruce E Kohut},
  journal={Journal of the American Academy of Dermatology},
  year={2007},
  volume={57 5},
  pages={767-74}
}
BACKGROUND An alternative to currently marketed topical minoxidil solutions is desirable. OBJECTIVE To assess the efficacy and safety of a new 5% minoxidil topical formulation in a propylene glycol-free foam vehicle in men with androgenetic alopecia (AGA). METHODS This was a 16-week, double-blind, placebo-controlled trial of 5% minoxidil topical foam (MTF) in 352 men, 18 to 49 years old. At week 16, 143 subjects continued on an open-label phase to collect 52 weeks of safety information on 5… CONTINUE READING

From This Paper

Topics from this paper.
33 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 33 extracted citations

Similar Papers

Loading similar papers…